|
Volumn 23, Issue 9, 2001, Pages 749-757
|
Esthesioneuroblastoma: The impact of treatment modality
|
Author keywords
Chemotherapy; Esthesioneuroblastoma; Radiation therapy
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CISPLATIN;
CYCLOPHOSPHAMIDE;
DACTINOMYCIN;
DOXORUBICIN;
ETOPOSIDE;
ADOLESCENT;
ADULT;
AGED;
ARTICLE;
CANCER ADJUVANT THERAPY;
CANCER CONTROL;
CANCER RADIOTHERAPY;
CANCER STAGING;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CONTROLLED STUDY;
ESTHESIONEUROBLASTOMA;
FEMALE;
FOLLOW UP;
HUMAN;
INTERMETHOD COMPARISON;
LYMPH NODE METASTASIS;
MALE;
MULTIMODALITY CANCER THERAPY;
PRIORITY JOURNAL;
PROGNOSIS;
TREATMENT OUTCOME;
ADOLESCENT;
ADULT;
AGED;
ANTINEOPLASTIC AGENTS;
COMBINED MODALITY THERAPY;
ESTHESIONEUROBLASTOMA, OLFACTORY;
FEMALE;
HUMANS;
LYMPHATIC METASTASIS;
MALE;
MIDDLE AGED;
NASAL CAVITY;
NEOPLASM STAGING;
NOSE NEOPLASMS;
RETROSPECTIVE STUDIES;
TREATMENT OUTCOME;
|
EID: 0034885017
PISSN: 10433074
EISSN: None
Source Type: Journal
DOI: 10.1002/hed.1107 Document Type: Article |
Times cited : (131)
|
References (26)
|